Boehringer Ingelheim International Gmbh

Ioannis Sapountzis

Heinz Stadtmueller

Steffen Steurer

Peter Ettmayer

Andreas Mantoulidis

Bodo Betzemeier

Daniel Kuhn

Martin Steegmaier

Irene Waizenegger

Christian Klein

Juergen Braunger

The present invention encompasses compounds of general formula (1) wherein

Pyrimidine compounds containing seven-membered fused ring systems

The present invention encompasses compounds of general formula (1), wherein the groups Rto Rand L are defined as in claim, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties. 

Chemical compounds

The present invention encompasses compounds of general formula (1) whereinA, B, X, Rto Rare defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.

Substituted pyrimidines for the treatment of diseases such as cancer

The present invention includes compounds of general formula (1) whereinA, X, Rand Rare defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.

Pyrimidine derivatives that inhibit FAK/PTK2

The present invention encompasses compounds of general formulae (1) and (1) wherein

Pyrimidines

The present invention encompasses compounds of general formula (1) wherein A, B, R-R, Rx and n are defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties. 

Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation

Compounds of general formula (1) whereinA, B, Rto R, Rm, n and p are defined as described in the specification, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and the use thereof [as] medicaments.

Pyrimidine inhibitors of PKTK2

The present invention encompasses compounds of general formula (1) wherein R-Rand n are defined as in claim, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties. 

2,4-diaminopyrimidine derivates as PTK2-inhibitors for the treatment of abnormal cell growth

The present invention encompasses compounds of general formula (1) wherein the groups Rto R, L, Q and n are defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Growing community of inventors

Vienna, Austria

Ioannis Sapountzis